Evidence map›Paper›PMID 33317212›Full record

ArticleBiomedicines2020

Authentication of Primary Murine Cell Lines by a Microfluidics-Based Lab-On-Chip System.

Yingfen Hong, Nikita Singh, Stefanos Bamopoulos, Enio Gjerga, Laura K Schmalbrock, Karl Balabanian, Markus Schick, Ulrich Keller, Matthias Wirth

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. LINC00844 suppresses tumor progression and predicts survival outcomes through inhibiting miR-19a-5p in cholangiocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Yingfen HongDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
Nikita SinghDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
Stefanos BamopoulosDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
Enio GjergaDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
Laura K SchmalbrockDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.ORCID 0000-0002-6080-6175
Karl BalabanianInstitut de Recherche Saint Louis, Université de Paris, EMiLy, Inserm U1160, F-75010 Paris, France.ORCID 0000-0002-0534-3198
Markus SchickDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
Ulrich KellerDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.ORCID 0000-0002-8485-1958
Matthias WirthDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.ORCID 0000-0002-8340-0872
Charité - Universitätsmedizin Berlin · DETechnical University of Munich · DEGerman Cancer Research Center · DEUniversity of London Institute in Paris · FR

Funding

Agence Nationale de la Recherche grant 17-CE14-0019Charité 3R Adding 3R valueChinese Scholarship Council Y.H.Deutsche Forschungsgemeinschaft SFB 1335Else-Kröner-Fresenius Stiftung EKFS 2016_A43Stiftung Charité Stiftung CharitéWalter-Schulz-Stiftung Walter-Schulz-Stiftung
6 · The paper itself

Abstract

The reliable authentication of cell lines is a prerequisite for the reproducibility and replicability of experiments. A common method of cell line authentication is the fragment length analysis (FLA) of short-tandem repeats (STR) by capillary electrophoresis. However, this technique is not always accessible and is often costly. Using a microfluidic electrophoresis system, we analyzed the quality and integrity of different murine cell lines by STR profiling. As a proof of concept, we isolated and immortalized hematopoietic progenitor cells (HPC) of various genotypes through retroviral transduction of the fusion of the estrogen receptor hormone-binding domain with the coding sequence of HoxB8. Cell lines were maintained in the HPC state with Flt3 ligand (FL) and estrogen treatment and could be characterized upon differentiation. In a validation cohort, we applied this technique on primary mutant Kras-driven pancreatic cancer cell lines, which again allowed for clear discrimination. In summary, our study provides evidence that FLA of STR-amplicons by microfluidic electrophoresis allows for stringent quality control and the tracking of cross-contaminations in both genetically stable HPC lines and cancer cell lines, making it a simple and cost-efficient alternative to traditional capillary electrophoresis.

Indexed as

authenticationbioanalyzerFLAHoxB8mouse cell linesSTR-PCR

Identifiers

PMID33317212
PMCPMC7763653
OpenAlexW3113205522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.